USPTO serial 77504998
NASALCARE
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Sep 29, 2009
- Examiner
- BENJAMIN, SARA NICOLE
- Law office
- GENERIC WEB UPDATE
What this means
Status 800 means the registration was renewed after acceptable combined Section 8 and Section 9 filings. The mark remains registered for another 10-year term with active federal protection. Calendar the next Section 8 and 9 deadline in 10 years and maintain monitoring.
Need help with NASALCARE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | [ Analgesic and muscle relaxant pharmaceutical preparations; Anti-diabetic pharmaceuticals; ] Antibacterial pharmaceuticals; [ Antimicrobial preparations for inhibiting microbiological decomposition in food, beverages, animal feed and pharmaceuticals; ] [ Antimicrobial preservatives for cosmetics and pharmaceuticals; ] [ Astringents; Bismuth preparations for pharmaceutical purposes; Cardiovascular pharmaceuticals; Dermatological pharmaceutical products; ] Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; [ Drug delivery agents in the form of a coating for macromolecule agents that facilitate the delivery of a wide range of pharmaceuticals; Gelatin capsules sold empty for pharmaceuticals; ] Homeopathic pharmaceuticals for use in the treatment of allergy and respiratory tract infections; [ Inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders; Inhalers filled with anti-infectives and anti-allergy pharmaceuticals; ] [ Injectable pharmaceuticals for treatment of anaphylactic reactions; Intravenous fluids used for rehydration, nutrition and the delivery of pharmaceutical preparations; Ocular pharmaceuticals; Pharmaceutical anti-allergic preparations and substances; ] Pharmaceutical antitussive-cold preparations; [ Pharmaceutical for the treatment of erectile dysfunction; Pharmaceutical preparation for the treatment of gout; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; ] Pharmaceutical preparations and substances for the treatment of infectious diseases, [ blood disorders, ] pain, inflammation [, sepsis, alopecia, obesity and cognitive disorders ] ; [ Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; Pharmaceutical preparations for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, the genitourinary system; for the treatment of inflammatory disorders; for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; ] Pharmaceutical preparations for the prevention and treatment of [ ocular disorders or diseases, for the treatment of ] bacteria-based diseases, [ and for the treatment of diabetes, ] and anti-infective preparations, antiviral preparations, antibiotics, antifungal preparations [ and vaccines ] ; [ Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for the treatment of heart rhythm disorders; Pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; ] Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for treating allergic rhinitis and asthma; [ Pharmaceutical preparations for treating diabetes; ] Pharmaceutical preparations for use in chemotherapy; [ Pharmaceutical preparations for use in urology; Pharmaceutical preparations for wounds; Pharmaceutical preparations, namely, antidepressants; Pharmaceutical preparations, namely, appetite suppressants; Pharmaceutical preparations, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; Pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; Pharmaceutical preparations, namely, anticoagulants; Pharmaceutical products and preparations against dry skin caused by pregnancy; Pharmaceutical products for the treatment of bone diseases; Pharmaceutical products for the treatment of joint disease; ] Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; [ Pharmaceutical solutions used in dialysis; Pharmaceuticals for the treatment of erectile dysfunction; ] Pharmaceuticals, namely, anti-infectives; [ Pharmaceuticals, namely, antihelmintics; ] [ Pharmaceuticals, namely, inducers of erections; Pharmaceuticals, namely, lipid lowering agents; Plant extracts for medical, veterinary and pharmaceutical purposes; ] [ Potassium preparations for pharmaceutical purposes; ] [ Radioactive pharmaceutical preparations for use in vivo diagnostic or therapeutic use; Synthetic peptides for pharmaceutical purposes; Unit dose capsules sold empty for pharmaceutical use; Vitamin and mineral preparations for use as ingredients in the food and pharmaceutical industry; Yeast or yeast extracts for medical, veterinary or pharmaceutical purposes ] | ACTIVE | Jan 2, 2007 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by TechWorld Corporation, Inc.
- Other trademarks owned by TechWorld Corporation, Inc.
- Other trademarks owned by TechWorld Corporation, Inc.
- Other trademarks in Class 005
- Similar marks named NASALCARE
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jan 7, 2020 | NA89 | NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED | — |
| Jan 7, 2020 | RNL1 | REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS) | The trademark registration was renewed for another 10-year term after acceptable maintenance filings. RNL1, RNL2, and RNL3 indicate which renewal cycle (first, second, or third 10-year term) was recorded. The registration remains active. |
| Jan 7, 2020 | 89AG | REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED | The USPTO accepted your combined Section 8 declaration and Section 9 renewal application. The registration is renewed for another 10-year term. The next combined maintenance filing will be due at the following 10-year anniversary. |
| Jan 6, 2020 | EROP | TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED | — |
| Jan 3, 2020 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jul 7, 2019 | PR89 | POST REGISTRATION ACTION MAILED - SEC. 8 & 9 | — |
| Jul 7, 2019 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Jun 21, 2019 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jun 21, 2019 | E89R | TEAS SECTION 8 & 9 RECEIVED | — |
| Sep 29, 2018 | REM2 | COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED | — |
| Oct 12, 2016 | NA85 | NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED | — |
| Oct 12, 2016 | C15A | REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK. | — |
| Sep 28, 2016 | EROP | TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED | — |
| Sep 27, 2016 | EROP | TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED | — |
| Jun 6, 2016 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| May 27, 2016 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Apr 8, 2016 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Apr 3, 2016 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Mar 28, 2016 | PR23 | POST REGISTRATION ACTION MAILED - SEC. 8 & 15 | — |
| Mar 25, 2016 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Mar 25, 2016 | E815 | TEAS SECTION 8 & 15 RECEIVED | — |
| Dec 13, 2014 | PR23 | POST REGISTRATION ACTION MAILED - SEC. 8 & 15 | — |
| Nov 24, 2014 | EROP | TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED | — |
| Oct 6, 2014 | PR23 | POST REGISTRATION ACTION MAILED - SEC. 8 & 15 | — |
| Oct 6, 2014 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Sep 30, 2014 | E815 | TEAS SECTION 8 & 15 RECEIVED | — |
| Sep 30, 2014 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Sep 29, 2009 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Aug 26, 2009 | TMBN | TTAB RELEASE CASE TO TRADEMARKS | — |
| Aug 26, 2009 | OP.T | OPPOSITION TERMINATED NO. 999999 | — |
| Aug 26, 2009 | OP.D | OPPOSITION DISMISSED NO. 999999 | — |
| Mar 12, 2009 | OP.I | OPPOSITION INSTITUTED NO. 999999 | — |
| Feb 4, 2009 | ETOF | EXTENSION OF TIME TO OPPOSE RECEIVED | — |
| Jan 20, 2009 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Dec 31, 2008 | NPUB | NOTICE OF PUBLICATION | — |
| Dec 16, 2008 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Dec 16, 2008 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Dec 16, 2008 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 16, 2008 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 16, 2008 | ALIE | ASSIGNED TO LIE | — |
| Dec 1, 2008 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Dec 1, 2008 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 3, 2008 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 3, 2008 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 3, 2008 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 26, 2008 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 26, 2008 | MDSM | NOTICE OF DESIGN SEARCH CODE MAILED | — |
| Jun 25, 2008 | NWAP | NEW APPLICATION ENTERED | — |